

Fig. 1A

Mouse
Human

MSSIGTGYDL SASTFSPDGR VFQVEYAMKA VENSSTAIGI RCKDGVVEGV
EKLVLKLYE EGSNKRLFNV DRHVGNAVAG LLADARSLAD IAREASNFR
SNFGYNIPK HLADRVAMYV HAYTLYSAVR PFGCSEMLGS YSANDGAOLY
MIDPSGVSYG YWCAIGKAR QAKTEIEKL QMKEMTCRDV VKEVAKIYYI
VHDEVKOKAF EELSWGEL TKGRHEIVPK DIREAEKYA KESLKEDES
DDNM

Fig. 1C

$\alpha 7$ subunit

Growth/LacZ+




Fig. 1D

PR39 IP.

$\alpha 7$

Fig. 1B

C terminal tails
Net Charge

Residue	Charge
$\alpha 1$ AERD	-1
$\alpha 2$ A	0
$\alpha 3$ KKHEEEAKAREKEKEQKDK	+1
$\alpha 4$ EKEKEENEKKKKAS	+2
$\alpha 5$	0
$\alpha 6$ EEPQKKAQPADEPAEKADPEMEH	-3
$\alpha 7$ AKESLKEEDESDDNM	-6

09276868.032699

Fig. 2A

ECV

ECV-E4

ECV-PR39

ECV Lactacystin

I- κ B

Fig. 2C

Control

PR39 10nM

MG132 10 μ M

Lactacystin 10 μ M

Fig. 2B

TNF- α

Control

Control

PR39 10nM


MG132 10 μ M

Lactacystin 10 μ M

Fig. 2D


Luciferase Activity

TNF α



04276868-032699

Inhibitor	Concentration	% of inhibition
Z-Leu-Leu-Leu-AMC	0	0
Z-Leu-Leu-Leu-AMC	100	~2
Z-Leu-Leu-Leu-AMC	250	~40
Z-Leu-Leu-Leu-AMC	350	~80
Z-Leu-Leu-Leu-AMC	500	~90
Z-Leu-Leu-Leu-AMC	1000	~95
β -lac	10 μ M	~90
MG132	10 μ M	~95



Condition	Product (µmol)
10	~20
50	~45
100	~65
250	~80
500	~90
1000	~95
β -lac 10 μ M	~15
MG132 10 μ M	~10

FD 36

[illegible]

Fig. 4A




Fig. 4B





Fig. 4C



Control

PR 39

Fig. 5A




Fig. 5C

Fig. 5B





Fig. 6




Fig. 7

09275858.032599